A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 Inhibitor, vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCI

Trial Profile

A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 Inhibitor, vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCI

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2013

At a glance

  • Drugs Clopidogrel (Primary) ; Elinogrel (Primary) ; Elinogrel (Primary)
  • Indications Embolism and thrombosis; Myocardial infarction
  • Focus Biomarker; Therapeutic Use
  • Acronyms INNOVATE-PCI
  • Sponsors Portola Pharmaceuticals
  • Most Recent Events

    • 02 Feb 2013 Planned number of patients changed from 650 to 800 as reported by European Clinical Trials Database.
    • 31 Aug 2010 Status changed from active, no longer recruiting to completed, according to the announcement of the presentation of results at ESC 2010 in a Portola Pharmaceuticals media release.
    • 29 Aug 2010 Results have been presented at SC Congress 2010: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top